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j.gheart.2012.12.003The year 2012 marks 65 years since the landmark
Framingham Heart Study began. With the dramatic rise in
coronary heart disease (CHD) during the ﬁrst half of the
20th century, the newly formed National Heart Institute
realized the signiﬁcant gap in knowledge about the causes
of CHD and embarked in 1947 on planning what was to
become the Framingham Heart Study. This study has
perhaps brought more to our understanding of the
underlying causes of cardiovascular disease than any other
study has.
Dr. Thomas Royal Dawber, Framingham’s ﬁrst director,
wrote the initial paper in 1950 [1] describing its design, and
later in 1957 [2], he described the study’s experience after 4
years of follow-up, where age and sex differences in CHD
and the frequent occurrence of sudden cardiac death as the
ﬁrst manifestation of CHD were noted. Here, too, the initial
observations regarding the signiﬁcance of elevated blood
pressure, cholesterol, and overweight in predicting future
CHD were described. Longtime study director Dr. William
Kannel’s 1961 publication [3], “Factors of Risk in the
Development of Coronary Heart Disease,” brought the term
risk factors into the commonmedical and lay vocabulary and
further described how speciﬁc levels of cholesterol, blood
pressure, and electrocardiographic left ventricular hyper-
trophy predicted future CHD incidence. Reports by Dr.
Kannel and many other investigators over ensuing decades
established the following as important predictors of CHD
risk: diabetes; hypertension; lipid components, such as low-
and high-density lipoproteins; and components of blood
pressure, including pulse pressure. Much of what we know
about the epidemiology of stroke and heart failure also
derives from the Framingham Heart Study. More recently,
Framingham has conducted sophisticated studies involving
genomics and cardiac biomarkers, as well as subclinical
vascular measures (such as coronary artery calcium
scores and pulse wave velocity). Beginning in 1971, the
second-generation cohort was enrolled, and in 2002, the
grandchildren of the original cohort were enrolled in the
third-generation cohort. More recent studies across these
generations and in collaboration with other observational
study cohorts have helped to establish novel predictors of
CHD and numerous other diseases and phenotypes. One of
the greatest contributions of the Framingham Heart Study is
the development of the Framingham Risk Score to deﬁne
a person’s likelihood of future CHD and acute events
associated therein, ranging from, initially, 10-year CHD risk
scores to total cardiovascular disease algorithms and,
currently, the development of lifetime risk scores.
The standardized methods ﬁrst developed by Fra-
mingham, including measurement of risk factors andGLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 1-2adjudicated methods for follow-up of cardiac events served
as an important prelude to future National Institutes of
Healthesponsored observational studies, including the
ARIC (Atherosclerosis Risk in Communities) study, the
CARDIA (Coronary Artery Risk Development in Young
Adults) study, the CHS (Cardiovascular Health Study), and
the MESA (Multiethnic Study of Atherosclerosis). These
studies and others continue the legacy that Framingham
began more than 60 years ago into the epidemiology of
cardiovascular diseases.
The ﬁeld of preventive cardiology has been the most
important contribution of the Framingham Heart Study [4].
The message regarding the importance of cessation of
cigarette smoking; pre-hypertension and blood pressure
control; hypercholesterolemia and deﬁning the optimal
levels of total and high-density lipoprotein cholesterol; and
the emerging threat of obesity, metabolic syndrome, and
diabetes has led to clinical trials to test the beneﬁts of
controlling the modiﬁable risk factors.
CHD, stroke incidence, and mortality have declined in
the United States and many developed countries over the
past decades in part because of lessons learned from Fra-
mingham. What we have learned from the experience in
high-income countries is now being translated into health
policies and population-wide efforts to combat CHD and
stroke in developing countries. In a recent presidential
advisory [5] written by leaders from the World Heart
Federation, American Heart Association, American College
of Cardiology, European Society of Cardiology, and the
European Heart Network, a goal was set to reduce non-
communicable disease mortality worldwide by 25% by the
year 2025, largely through global targets to reduce cigarette
smoking, sodium intake, obesity, and through the promo-
tion of heart-healthy eating and regular physical activity.
This issue of Global Heart is dedicated to celebrating the
legacy of the FraminghamHeart Study.We convened a panel
of renowned experts, including key Framingham investiga-
tors, to describe the key contributions of the Framingham
Heart Study; the design and creation of the study; initial
ﬁndings regarding CHD incidence; the development of risk
assessment methods; the roles of blood pressure, dyslipi-
demia, diabetes, cigarette smoking, and genetics; and lessons
learned regarding stroke and heart failure from this land-
mark study. Many authors of this special issue of Global
Heart were also inspired by the work of Framingham’s
original investigators and have also spent decades of their
research and/or medical practice dedicated to preventive
cardiology. The authors of this special issue collectively have
contributed more than 250 years of dedication and well over
1,000 publications to the ﬁeld.1
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2We hope this issue will serve as an inspiration to many
more generations of investigators who will continue to
examine new hypotheses that may further expand what we
have learned so far. What began in the small community of
Framingham, Massachusetts, USA, 65 years ago has
informed how we prevent and treat cardiovascular diseases
and will hopefully continue to have a lasting impact
worldwide on reducing CHD, stroke, and other non-
communicable diseases. The burden of the effort lies
among researchers, healthcare providers, teachers, and
governmental policy makers to make the lessons learned
from Framingham a priority in their work.REFERENCES
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